Gilead maintained by Merrill at neutral

Gilead Sciences Inc. was maintained by Merrill Lynch analyst Eric Ende at a neutral rating after Gilead and Bristol-Myers Squibb announced data supporting bioequivalence of a single pill fixed dose triplet combination of Truvada plus Sustiva. The partners plan to submit a sNDA in the second quarter of 2006, Merrill said, adding that it won't be a key revenue driver for Gilead because the combination is the most commonly prescribed for HIV patients receiving Truvada already. Shares of the Foster City, Calif., biopharmaceutical company were up 88 cents, or 1.54%, at $57.91 on volume of 3,960,641 shares versus the three-month running average of 4,822,760 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.